Vtx-2337-Hn-001- A Phase 1B Multicenter Pre-Surgical Study To Evaluate Immune Biomarker Modulation In Response To Motolimod (Vtx-2337) In Combination With Nivolumab In Subjects With Resectable Squamous Cell Carcinoma Of The Head And Neck (Scchn)
Posted Date: May 6, 2021
- Investigator: Alice Tang
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The main purpose of this study is to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like receptor 8 (TLR 8) agonist motolimod delivered either subcutaneously (SC) or by intratumoral injection (IT) in subjects with squamous cell carcinoma of the head and neck (SCCHN).
Criteria:
New Clinical Or Pathologic Diagnosis Of Resectable Hpv+ Or Hpv- Scchn Of The Oral Cavity, Pharynx, Or Larynx,
Keywords:
Head And Neck Cancer, Hnscc
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com